Literature DB >> 1560239

Increased expression of beta-amyloid protein precursor and microtubule-associated protein tau during the differentiation of murine embryonal carcinoma cells.

K Fukuchi1, S S Deeb, K Kamino, C E Ogburn, A D Snow, R T Sekiguchi, T N Wight, H Piussan, G M Martin.   

Abstract

Expression of the genes encoding the beta/A4 amyloid protein precursor (APP) and microtubule-associated protein tau was studied in an embryonal carcinoma cell line (P19) that differentiates in vitro into cholinergic neurons after treatment with retinoic acid. Expression of APP increased 34- (mRNA) and 50-fold (protein) during neuronal differentiation; APP-695 accounted for most of this increase. These remarkable increases in APP expression coincided with a proliferation of neuronal processes and with an increase in content of tau mRNA. Moreover, subsequent decreases in the levels of APP and tau mRNA coincided with the onset of the degeneration of the neuronal processes. Immunocytochemical staining suggested that greater than 85% of the P19-derived neurons are cholinergic and that APP is present in the neuronal processes and cell bodies. These results suggest that APP may play an important role in construction of neuronal networks and neuronal differentiation and also indicate that this embryonal carcinoma cell line provides an ideal model system to investigate biological functions of APP and the roles of APP and tau protein in development of Alzheimer's disease in cholinergic neurons.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1560239     DOI: 10.1111/j.1471-4159.1992.tb10063.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  10 in total

1.  The gamma -secretase-cleaved C-terminal fragment of amyloid precursor protein mediates signaling to the nucleus.

Authors:  Y Gao; S W Pimplikar
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-11       Impact factor: 11.205

2.  Culture density regulates both the cholinergic phenotype and the expression of the CNTF receptor in P19 neurons.

Authors:  D Parnas; M Linial
Journal:  J Mol Neurosci       Date:  1997-04       Impact factor: 3.444

Review 3.  The role of the amyloid protein precursor (APP) in Alzheimer's disease: does the normal function of APP explain the topography of neurodegeneration?

Authors:  D H Small
Journal:  Neurochem Res       Date:  1998-05       Impact factor: 3.996

4.  Accumulation of amyloid-beta protein in exocrine glands of transgenic mice overexpressing a carboxyl terminal portion of amyloid protein precursor.

Authors:  K Fukuchi; L Li; M Hart; J R Lindsey
Journal:  Int J Exp Pathol       Date:  2000-08       Impact factor: 1.925

Review 5.  Evidence for defective retinoid transport and function in late onset Alzheimer's disease.

Authors:  Ann B Goodman; Arthur B Pardee
Journal:  Proc Natl Acad Sci U S A       Date:  2003-02-25       Impact factor: 11.205

6.  Increased expression of beta-amyloid precursor protein during neuronal differentiation is not accompanied by secretory cleavage.

Authors:  A Y Hung; E H Koo; C Haass; D J Selkoe
Journal:  Proc Natl Acad Sci U S A       Date:  1992-10-15       Impact factor: 11.205

7.  Activity assays of nine heterogeneous promoters in neural and other cultured cells.

Authors:  K Fukuchi; M G Hearn; S S Deeb; A C Smith; N Dang; J Miyazaki; M Bothwell; G M Martin
Journal:  In Vitro Cell Dev Biol Anim       Date:  1994-05       Impact factor: 2.416

Review 8.  Three independent lines of evidence suggest retinoids as causal to schizophrenia.

Authors:  A B Goodman
Journal:  Proc Natl Acad Sci U S A       Date:  1998-06-23       Impact factor: 11.205

Review 9.  Insights into the physiological function of the β-amyloid precursor protein: beyond Alzheimer's disease.

Authors:  Edgar Dawkins; David H Small
Journal:  J Neurochem       Date:  2014-03-07       Impact factor: 5.372

10.  Increased expression of retinoic acid-induced gene 1 in the dorsolateral prefrontal cortex in schizophrenia, bipolar disorder, and major depression.

Authors:  Johannes Haybaeck; Magdalena Postruznik; Christine L Miller; Jeannette R Dulay; Ida C Llenos; Serge Weis
Journal:  Neuropsychiatr Dis Treat       Date:  2015-02-04       Impact factor: 2.570

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.